BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
investors on advancing late-stage programs and commercial traction for its ATTR-CM therapy Attruby and other pipeline assets. These financing and pipeline developments point to BridgeBio's effort to strengthen its balance sheet while supporting growing demand for Attruby and progress toward potential regulatory milestones. We'll now examine how BridgeBio's new US$550,000,000 fixed-income offering may influence the company's investment narrative and risk-reward profile. We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. To own BridgeBio, you need to believe that Attruby can sustain its early commercial traction while late stage programs like BBP-418 convert into approved products, gradually reducing reliance on a single drug. The new US$550,000,000 senior subordinated notes appear primarily balance sheet focused and do not materially change the near term clinical catalyst around BBP-418, but they do matter for t
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027GlobeNewswire
- Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]Yahoo! Finance
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]Yahoo! Finance
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027GlobeNewswire
- BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- 1/8/26 - Form 144
- BBIO's page on the SEC website